Inhaled antibiotics for the treatment of pneumonia. [Review]
Citation: Current Opinion in Pulmonary Medicine. 25(3):289-293, 2019 05.PMID: 30562188Institution: MedStar Washington Hospital CenterDepartment: Medicine/Pulmonary-Critical CareForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: *Amikacin/ad [Administration & Dosage] | *Anti-Bacterial Agents/ad [Administration & Dosage] | *Pneumonia, Bacterial/dt [Drug Therapy] | *Pneumonia, Ventilator-Associated/dt [Drug Therapy] | Administration, Inhalation | HumansYear: 2019Local holdings: Available online from MWHC library: 1999 - presentISSN:- 1070-5287
Item type | Current library | Collection | Call number | Status | Date due | Barcode |
---|---|---|---|---|---|---|
Journal Article | MedStar Authors Catalog | Article | 30562188 | Available | 30562188 |
Available online from MWHC library: 1999 - present
PURPOSE OF REVIEW: To describe recent developments in trials exploring inhaled antibiotics for treating severe pneumonia.
RECENT FINDINGS: Three recent randomized studies investigated the potential role for aerosolized antibiotics for gram-negative pneumonia in ventilated patients. One single center, nonblinded investigation suggested a benefit with inhaled amikacin for resistant gram-negative infections. However, two multicenter, blinded trials found no benefit to adjunctive nebulized amikacin for severe gram-negative pneumonia.
SUMMARY: Well done clinical trials do not support the routine use of inhaled amikacin for pneumonia in ventilated patients. There may be a potential role for aerosolized antibiotics when other options are limited.
English